PHARMACOECONOMIC ANALYSIS OF END STAGE RENAL DISEASED PATIENTS UNDERGOING HEMODIALYSIS
The increased prevalence of end stage renal disease (ESRD) in India and the treatment options are dialysis or kidney transplantation. The availability and affordability are two important issues in treatment of ESRD. Hemodialysis (HD) is inaccessible and not affordable by majority of population in India. To assess the direct and indirect cost of hemodialysis patients. This was a prospective, observational and interventional study conducted for 5 months period in a secondary care hospital. Patients undergoing hemodialysis were selected for the study. A 25 members undergoing hemodialysis were selected and the data was obtained along with cost details of 1025 sessions were studied. Health cost analyzed which includes medical (dialysis, erythropoietin, medications and investigations) and nonmedical costs (wages, food and transportation). The total cost per session was found to be 4265, total 1025 sessions were studied. In that 52% contributes direct medical costs, 19% contributes non-medical costs and 29% contributes indirect medical costs, since the patients were paying from their own pockets only the middle class people can undergo Hemodialysis. The health cost of treating a patient on HD in India is around Rupees 10,000-12,000 per month in subsidized dialysis units, and in private hospitals the health cost of treating a patient is around Rupees 20,000 and 30,000. This study concludes that medical cost spent more than other cost in patients undergoing hemodialysis units